Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) continues to expand its clinic footprint worldwide and has opened its first medical cannabis clinic Zerenia in Brazil.
On Monday, the Toronto-headquarter cannabis operator with primary operations in Colombia announced the inauguration of its Ipanema, Rio de Janeiro clinic with a capacity of 23,000 patient consultations per year.
The clinic will have 13 doctors for in-person and telehealth consultations that will prescribe cannabinoid-based medications to treat chronic pain, neurological, dermatological and other pathologies.
The clinic’s operations will be supported by strategic partnerships with doctors and patient associations including CANNAB in Salvador de Bahia and leading medical distributors as TAIMIN in Rio de Janeiro and Sao Paulo.
This fall, the company expects to launch more of its THC products in Brazil.
“Khiron has developed a unique, successful, and sustainable model with the implementation of Zerenia in Colombia, Perú, and the United Kingdom,” said CEO Alvaro Torres.
“Brazil is Latin America´s largest addressable market with more than 210 million people and we believe that our Zerenia model will replicate the success we have experienced around the world,” he added.
“We have served more than 25,000 individual patients across the globe through our model, with high peer patient acquisition and retention rates.”
Read more: Khiron reaches new medical revenue records in Q1
Read more: Khiron to acquire EU-GMP-certified German pharmaceuticals manufacturer
“Brazil continues to experience exponential growth in prescribing doctors and demand for medical cannabis products by patients. Zerenia Rio, is positioned as a comprehensive and humanized pioneer in patient health service and prevention to improve the quality of life of Brazilian families,” Zerenia Rio medical director Eduardo Faveret said.
“We have assembled a multidisciplinary medical team that covers diverse medical cannabis specialties and treatments, which makes our Zerenia Rio clinic unique in Brazil,” he added.
NEWSLETTER
Subscribe to our newsletter
Want the best of alternative investing news including cannabis, psychedelics, technology, and trending industries sent to your inbox?
Sign up to get our stories of the week sent to your inbox.
We will never sell your information or spam you. By entering your email, you are agreeing to our terms of use and understand our privacy policy.
